Across TCGA pan-cancer cohorts, BCCIP Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BCCIP data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher BCCIP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCCIP expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
READ, HNSC, and UCEC are the cancer types where BCCIP Mutation most reproducibly stratifies survival.